Alpenglow Biosciences® participated in a survey to identify key issues in 3D Spatial Biology presented by Thomas Kroneis, PhD, Chair of the ESSB 3D Working Group.
Published
Signal category
Research & Knowledge
Quote
“On behalf of The European Society for Spatial Biology (ESSB) e.V. + 3D Working group I am pleased to recirculate this request from Thomas Kroneis, PhD, and Chair of ESSB 3D Working Group.”
— Steve Pemberton|Alpenglow Biosciences® team
Company
Alpenglow Biosciences®
3D tissue imaging data for spatial biology
- Industry
- Biotechnology Research
- Location
- Seattle, US
- Company size
- 32 employees
Alpenglow Biosciences accelerates drug development and improves clinical diagnostics with light-sheet 3D tissue imaging and AI-powered analysis for spatial biology and digital pathology. The Aurora 3D spatial biology platform digitizes intact tissue samples, delivering quantitative 3D datasets while preserving tissue for molecular analysis Partners use Alpenglow Biosciences to: - Discover new biology in intact tissue - Generate analysis-ready volumetric datasets and spatial metrics - Support AI model development with ground truth 3D data - Improve decision-making in preclinical and clinical programs Five of the top 10 pharmaceutical companies collaborate with Alpenglow to uncover new insights, streamline timelines, and improve success rates across their pipelines. We are hiring talented individuals for roles in business development, wet lab, hardware, and software.
Founded 2018